Sutezolid

Drug Profile

Sutezolid

Alternative Names: PF-02341272; PF-2341272; PNU-100480; U 100480; U 101244; U 101603

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator John Hopkins University; Pharmacia Corporation
  • Developer Sequella
  • Class Acetamides; Amides; Antibacterials; Oxazolidinones; Small molecules; Thiamorpholines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 04 Apr 2017 Sutezol is still in phase I trials for Tuberculosis in USA (Sequella email, April 2017)
  • 04 Apr 2017 Sutezol is still in phase II trials for Tuberculosis in South Africa (Sequella email, April 2017)
  • 24 Mar 2017 Sutezolid sub-licensed to Global Alliance for TB Drug Developmentworldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top